Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Ana Planinc"'
Autor:
Martina Bogeljić Patekar, Vibor Milunović, Karla Mišura Jakobac, Dražen Perica, Inga Mandac Rogulj, Marin Kursar, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica, Vol 57., Iss 3., Pp 542-553 (2018)
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for ritu
Externí odkaz:
https://doaj.org/article/a532d7dede5040d49da04c819b38aa99
Autor:
Vibor Milunović, Martina Bogeljić Patekar, Karla Mišura Jakubac, Inga Mandac Rogulj, Delfa Radić-Krišto, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica, Vol 56., Iss 1., Pp 143-156 (2017)
Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review is to present da
Externí odkaz:
https://doaj.org/article/56a6185676fe49db91e004668b948a8e
Publikováno v:
Acta Medico-Biotechnica. 5:33-39
Purpose: Atypical glandular cells (AGC) are often associated with clinically significant lesions, but the interpretation of AGC and the associated lesions on Pap smears remains challenging, even for experienced cytopathologists. The frequency and his
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93d1e414379cef34e8ed3a101bbf5871
https://doi.org/10.18690/actabiomed.73
https://doi.org/10.18690/actabiomed.73
Autor:
Dean Mileta, Ingrid Prkačin, Ana Planinc Peraica, Gordana Cavrić, Inga Mandac Rogulj, Višnja Mandac Bajan
Publikováno v:
Liječnički vjesnik. 141:247-249
Myelodysplastic syndromes (MDS) are a group of clonal disorders arising from hematopoietic stem cells and are generally characterized by inefficient hematopoiesis and dysplasia. The International Prognostic Scoring Sytem (IPSS) is an important standa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cedb55465a84b71a23df5b0dfcf9b09
https://doi.org/10.26800/lv-141-7-8-32
https://doi.org/10.26800/lv-141-7-8-32
Autor:
Ana Reschner, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić, Inga Mandac Rogulj, Gordana Kaić, Marin Kursar, Marko Martinović, Morana Kosanović-Bajić, Ana Planinc-Peraica
Publikováno v:
Liječnički vjesnik. 141
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d5f3de95ead574f4c841c5ae0e9b6ae
https://doi.org/10.26800/lv-141-9-10-39
https://doi.org/10.26800/lv-141-9-10-39
Autor:
Ingrid Prkačin, Inga Mandac Rogulj, Višnja Mandac Bajan, Ana Planinc Peraica, Gordana Cavrić, Dean Mileta
Publikováno v:
Liječnički vjesnik
Volume 141
Issue 7-8
Volume 141
Issue 7-8
Mijelodisplastični sindrom (MDS) grupa je klonskih mijeloidnih poremećaja s heterogenom kliničkom slikom, a najveći broj komplikacija posljedica je citopenija koje su karakteristično obilježje. Etiologija nije dovoljno poznata. Internacionalni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______951::d0b3d6edd878e813d5352559519ff89f
https://hrcak.srce.hr/225772
https://hrcak.srce.hr/225772
Autor:
Johan Viaene, Serge Van Praet, Pierre Van Antwerpen, Cédric Delporte, Florence Rappez, Yvan Vander Heyden, Ana Planinc, Bieke Dejaegher
Publikováno v:
Analytical and Bioanalytical Chemistry. 409:477-485
Therapeutic proteins are among the top selling drugs in the pharmaceutical industry. More than 60 % of the approved therapeutic proteins are glycosylated. Nowadays, it is well accepted that changes in glycosylation may affect the safety and the effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fac99dcd34ac5fea48c34699150f83e9
https://doi.org/10.1007/s00216-016-9683-9
https://doi.org/10.1007/s00216-016-9683-9
Autor:
Slobodanka Ostojić, Ekaterina Bulycheva, Ana Planinc-Peraica, Vibor Milunović, Inga Mandac Rogulj
Publikováno v:
European Journal of Haematology. 96:553-563
Myelodysplastic syndromes (MDS) are heterogeneous group of hematologic disorders of mostly elderly and based on distinct clinical phenotypes. Current paradigm of their pathogenesis relies on somatic gene mutations combined with the predisposing defec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aabc8bf28760b6c0e674623eb06b895e
https://doi.org/10.1111/ejh.12735
https://doi.org/10.1111/ejh.12735
Autor:
Karla Mišura Jakobac, Ana Planinc-Peraica, Marin Kursar, Inga Mandac Rogulj, Dražen Perica, Vibor Milunović, Martina Bogeljić Patekar, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica
Acta Clinica Croatica, Vol 57, Iss 3., Pp 542-553 (2018)
Acta Clinica Croatica, Vol 57, Iss 3., Pp 542-553 (2018)
SUMMARY – The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently appro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a7f03372b0f4055f73828f05fafe24c
https://doi.org/10.20471/acc.2018.57.03.18
https://doi.org/10.20471/acc.2018.57.03.18
Autor:
Martina Bogeljić Patekar, Vibor Milunović, Karla Mišura Jakobac, Dražen Perica, Inga Mandac Rogulj, Marin Kursar, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta clinica Croatica
Volume 57.
Issue 3.
Volume 57.
Issue 3.
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for ritu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::aad5ca23ab7ca79428ebc324897596b2
https://www.bib.irb.hr/1089253
https://www.bib.irb.hr/1089253
